Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacodynamic Biomarkers of Upadacitinib, Tofacitinib, and Baricitinib in Healthy Subjects
NCT07843693Phase 1Recruiting
- Sponsor
- AbbVie Inc.
- Start
- Aug 2026
- Primary completion
- Dec 2026
- Countries
- 1
01
Overview
Phase 1, open-label trial of upadacitinib, tofacitinib oral solution and baricitinib (5 arms), sponsored by AbbVie Inc. Primary endpoints: Number of Participants With Treatment Emergent Adverse Events at 44 days, Average plasma concentration of Upadacitinib at 44 days and 8 more. Started Aug 2026; status: recruiting.
02
Drugs
upadacitinibtofacitinib oral solutionbaricitinib
Beyond the preview
Go deeper on NCT07843693.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07843693.